Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second- or third-line treatment of patients with EGFR wild-type advanced non-small cell lung cancer (ECOG-ACRIN 1512): a phase 2 randomised controlled trial

BACKGROUND: Erlotinib is approved for the treatment of all patients with advanced non-small cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and AXL, which are implicated in lu...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Lancet Oncol
Egile Nagusiak: Neal, Joel W., Dahlberg, Suzanne E., Wakelee, Heather A., Aisner, Seena C., Bowden, Michaela, Huang, Ying, Carbone, David P., Gerstner, Gregory J., Lerner, Rachel E., Rubin, Jerome L., Owonikoko, Taofeek K., Stella, Philip J., Steen, Preston D., Khalid, Ahmed Ali, Ramalingam, Suresh S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5154681/
https://ncbi.nlm.nih.gov/pubmed/27825638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30561-7
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak